BEACON pharmaceuticals Ltd. (BPL), one of Bangladesh’s leading generic pharmaceutical companies, announced the launch of ‘Crizotinib’ internationally for the treatment of metastatic Non-Small Cell Lung Cancer under the brand name ‘Crizonix’.Crizonix is the 1st global generic of Crizotinib.
The product has been approved by FDA and has been recommended as a first-line treatment for both ALK + and ROS-1+ NSCLC patient.Crizotinib is the first and only drug of its kind which bagged the FDA approval. It will be marketed and distributed by BEACON pharmaceuticals Ltd. Solely.
Commenting on the launch of the product, Mr. EbadulKarim, Managing Director of BPL said, “being the number 1 oncology company in Bangladesh,wealways try to support global cancer patient by offering latest drug at affordable price”. “We are getting huge queries from across the world” said Mr.Monjur, Head of Business Development Department, BPL. “It has been an exciting journey for us as we believe Crizonix will be a cost-effective treatment option to patients across the globe.
The product is manufactured in a dedicated oncology facility.